BIEL: The 4‑PR Path to Copper (Momentum Engine)
The June 17 PR didn’t move the PPS because it added no new catalysts — no numbers, no channels, no timelines, no launch, no traction metrics .
To reach COPPER, BIEL needs a sequenced PR engine that builds pressure every 7–14 days until the market sees a complete, investable story.
Below is the optimized version — the 4‑PR Momentum Engine.
PR #1 — “Numbers Hit the Table”
Timing: Immediately
Purpose: Turn the vague “initial purchase order” into a real catalyst.
Headline:
Electrome Issues $X Initial Purchase Order to BioElectronics as Commercial Launch Buildout Accelerates
What must be included:
Actual PO dollar value
Unit count
Confirmation this is the first of multiple orders
Manufacturing capacity expansion
Electrome’s launch timeline (e.g., Q3)
Electrome quote confirming reorder expectations
Why it moves PPS:
It converts “manufacturing underway” into quantified demand, which the current PR lacks .
PR #2 — “Channel Expansion”
Timing: 5–10 days after PR #1
Purpose: Show real distribution, not just “preparing” or “building” systems .
Headline:
Electrome Secures Initial Retail & Digital Distribution Channels for ActiPatch Rollout
What must be included:
1–3 named retail or digital channels
Electrome ecommerce launch date
Integration into Electrome’s AI-native funnel
Early demand indicators (waitlist, signups, pre-launch interest)
Why it moves PPS:
It proves traction, not theory.
PR #3 — “Clinical & Regulatory Leverage”
Timing: 7–14 days after PR #2
Purpose: Add legitimacy and expand TAM.
Headline:
BioElectronics Expands Clinical & Regulatory Positioning to Support Electrome’s National Rollout
What must be included:
New clinical data summary
New application areas (post-op, chronic pain, sports recovery)
Regulatory updates (EU, Canada, VA, etc.)
Tie-in to Electrome’s marketing strategy
Why it moves PPS:
It reframes BIEL as a validated medical technology, not a consumer gadget — something the current PR fails to do beyond mentioning FDA clearance .
PR #4 — “Launch Activation”
Timing: 10–20 days after PR #3
Purpose: Deliver the breakout catalyst.
Headline:
Electrome Launches National AI‑Driven Consumer Campaign for ActiPatch With Multi‑Channel Rollout
What must be included:
Official launch date
Marketing budget range
Influencer/partnership confirmations
Early sales data (even small numbers matter)
Reorder pipeline confirmation
CEO quotes about scaling
Why it moves PPS:
This is the activation event — the moment the market sees real demand, real marketing, real revenue, real scale .
Optional PR #5 — “Momentum Amplifier”
Timing: 3–7 days after PR #4
Purpose: Sustain the breakout.
Headline:
BioElectronics Reports Surge in Consumer Demand Following Electrome Launch Campaign
What must be included:
Early sales velocity
Conversion rates
Reorder rate
Customer satisfaction metrics
Testimonials
Next-phase marketing plans
Why it moves PPS:
It proves the launch wasn’t a one-day spike — it’s a trend .
Why This Sequence Works
Because it fixes every weakness in the recent PR:
No numbers
No scale
No timelines
No channels
No launch date
No revenue visibility
No clinical expansion
No traction metrics
Each PR adds one missing piece until the market sees a complete, investable, scalable commercial story.
The June 17 PR didn’t move the PPS because it added no new catalysts — no numbers, no channels, no timelines, no launch, no traction metrics .
To reach COPPER, BIEL needs a sequenced PR engine that builds pressure every 7–14 days until the market sees a complete, investable story.
Below is the optimized version — the 4‑PR Momentum Engine.
PR #1 — “Numbers Hit the Table”
Timing: Immediately
Purpose: Turn the vague “initial purchase order” into a real catalyst.
Headline:
Electrome Issues $X Initial Purchase Order to BioElectronics as Commercial Launch Buildout Accelerates
What must be included:
Actual PO dollar value
Unit count
Confirmation this is the first of multiple orders
Manufacturing capacity expansion
Electrome’s launch timeline (e.g., Q3)
Electrome quote confirming reorder expectations
Why it moves PPS:
It converts “manufacturing underway” into quantified demand, which the current PR lacks .
PR #2 — “Channel Expansion”
Timing: 5–10 days after PR #1
Purpose: Show real distribution, not just “preparing” or “building” systems .
Headline:
Electrome Secures Initial Retail & Digital Distribution Channels for ActiPatch Rollout
What must be included:
1–3 named retail or digital channels
Electrome ecommerce launch date
Integration into Electrome’s AI-native funnel
Early demand indicators (waitlist, signups, pre-launch interest)
Why it moves PPS:
It proves traction, not theory.
PR #3 — “Clinical & Regulatory Leverage”
Timing: 7–14 days after PR #2
Purpose: Add legitimacy and expand TAM.
Headline:
BioElectronics Expands Clinical & Regulatory Positioning to Support Electrome’s National Rollout
What must be included:
New clinical data summary
New application areas (post-op, chronic pain, sports recovery)
Regulatory updates (EU, Canada, VA, etc.)
Tie-in to Electrome’s marketing strategy
Why it moves PPS:
It reframes BIEL as a validated medical technology, not a consumer gadget — something the current PR fails to do beyond mentioning FDA clearance .
PR #4 — “Launch Activation”
Timing: 10–20 days after PR #3
Purpose: Deliver the breakout catalyst.
Headline:
Electrome Launches National AI‑Driven Consumer Campaign for ActiPatch With Multi‑Channel Rollout
What must be included:
Official launch date
Marketing budget range
Influencer/partnership confirmations
Early sales data (even small numbers matter)
Reorder pipeline confirmation
CEO quotes about scaling
Why it moves PPS:
This is the activation event — the moment the market sees real demand, real marketing, real revenue, real scale .
Optional PR #5 — “Momentum Amplifier”
Timing: 3–7 days after PR #4
Purpose: Sustain the breakout.
Headline:
BioElectronics Reports Surge in Consumer Demand Following Electrome Launch Campaign
What must be included:
Early sales velocity
Conversion rates
Reorder rate
Customer satisfaction metrics
Testimonials
Next-phase marketing plans
Why it moves PPS:
It proves the launch wasn’t a one-day spike — it’s a trend .
Why This Sequence Works
Because it fixes every weakness in the recent PR:
No numbers
No scale
No timelines
No channels
No launch date
No revenue visibility
No clinical expansion
No traction metrics
Each PR adds one missing piece until the market sees a complete, investable, scalable commercial story.
1
